Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionClosed to enrollment Location: Multiple care centres across the US

    Study of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor, in children 2-5 years old with cystic fibrosis (Part B) (VX20-445-111 PART B ) , protocol number VX20-445-111 PART B NCT04537793

    This study will look at the safety and effectiveness of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®), in children ages 2-5 years old with CF. These drugs are intended to help CFTR protein function closer to normal.

    • Age:

      2 Years to 5 Years

    • Mutation(s):

      Two Copies F508del or One Copy F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      9

    • Length of Participation:

      32 weeks

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple care centres across the US

    Study to evaluate the effects of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor in children (PROMISE Pediatric Cohort) (PROMISE-OB-18 - Pediatric Cohort) , protocol number NCT04613128

    This observational study will measure the effects of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor, in children with CF. These drugs are intended to help CFTR protein function closer to normal. This study will look at how treatment with the triple-combination therapy affects children with CF across many different aspects of the disease.

    • Age:

      6 to 11 Years

    • Mutation(s):

      Two Copies F508del or One Copy F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      2 Years

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Not specified

    Study to evaluate inhaled AP-PA02 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (Armata Phase 1b/2 SAD) , protocol number Armata Phase 1b/2 SAD NCT04596319

    This study will look at the safety and tolerability of inhaled AP-PA02, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      60% or greater

    • Number of Visits:

      8

    • Length of Participation:

      29 days

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Not specified

    Study to evaluate inhaled AP-PA02 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (Armata Phase 1b/2 MAD) , protocol number Armata Phase 1b/2 MAD NCT04596319

    This study will look at the safety and tolerability of inhaled AP-PA02, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      60% or greater

    • Number of Visits:

      10

    • Length of Participation:

      31 days

    Contact us about this clinical Trial >
  • OtherRecruiting Location: Australia

    A Phase 2 Study to evaluate the safety, tolerability, PK and PD in cystic fibrosis patients with at least 1 G542X Allele , protocol number ELX-02 NCT04126473

    This is a Phase 2 open label study to evaluate the safety, tolerability, PK and PD of multiple dose levels of SC administered ELX-02 in patients with CF with at least one G542X allelle.

    • Age:

      16 Years and Older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      40%

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • ObservationalRecruiting Location: Alfred Hospital, Victoria

    Modified Release Posaconazole in patients with cystic fibrosis , protocol number NCT03421366

    A prospective single centre observational cohort of patients with cystic fibrosis to determine whether adequate serum levels of posaconazole, after administration of the newer modified release once daily oral formation, can be achieved.

    • Age:

      18 Years and Older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple care centres across the US

    Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN Part B) , protocol number NCT04509050

    This two-part observational study will look at the effects of CFTR modulators on growth in young children with CF. These drugs are intended to help CFTR protein function closer to normal.

    • Age:

      Less than 6 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      2 Years

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple care centres across the US

    Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN Part A) , protocol number NCT04509050

    This two part study will look at the effects of CFTR modulators on growth in young children with CF. These drugs are intended to help CFTR protein function closer to normal.

    • Age:

      0 Years to 4 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      3 Years

    Contact us about this clinical Trial >
  • OtherRecruiting Location: Australia

    A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in subjects with cystic fibrosis who are less than 24 months of age and have an Ivacaftor-Responsive CFTR Mutation , protocol number NCT02725567

    The purpose of this study is to evaluate the safety of ivacaftor treatment, and PK of ivacaftor and metabolites in subjects with cystic fibrosis (CF) who are <24 months of age at treatment initiation and have a CF transmembrane conductance regulator (CFTR) gene gating mutation

    • Age:

      Maximum 24 months of Age

    • Mutation(s):

      One copy F508del

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherRecruiting Location: Queensland Children's Hospital & The Children's Hospital Westmead

    A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in subject 6 through 11 years of Age with cystic fibrosis and F/MF genotypes , protocol number NCT04353817

    This study will evaluate the efficacy and safety of elexacaftor (ELX) / tezacaftor (TEZ) / ivacaftor (IVA) triple combination (TC) in subjects 6 through 11 years of age with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function (MF) mutation (F/MF genotypes).

    • Age:

      6 Years through to 11 Years

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      70%

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • Displaying results 21-30 (of 225)
     |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|